{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T07:53:38Z","timestamp":1683100418333},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1097\/iae.0000000000000359","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T15:35:16Z","timestamp":1413300916000},"page":"660-666","source":"Crossref","is-referenced-by-count":9,"title":["EFFICACY OF INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR STAGE 4 RETINOPATHY OF PREMATURITY"],"prefix":"10.1097","volume":"35","author":[{"given":"Hui-Chen","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui-Mei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ting","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Kang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.2004-1413","article-title":". The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study.","volume":"116","author":"Good","year":"2005","journal-title":"Pediatrics"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2009.04.018","article-title":"Incidence of retinopathy of prematurity in the United States: 1997 through 2005.","volume":"148","author":"Lad","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archopht.1984.01040030908011","article-title":"The Committee for the Classification of Retinopathy of Prematurity.","volume":"102","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(88)90820-3","article-title":"Epidemiology of retinopathy of prematurity.","volume":"2","author":"Ng","year":"1988","journal-title":"Lancet"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/eye.1992.46","article-title":"Natural history of retinopathy of prematurity: a prospective study.","volume":"6","author":"Fielder","year":"1992","journal-title":"Eye (Lond)"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ophtha.2005.03.031","article-title":"Anatomic success rate after 3-port lens-sparing vitrectomy in stage 4A or 4B retinopathy of prematurity.","volume":"112","author":"Lakhanpal","year":"2005","journal-title":"Ophthalmology"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0161-6420(98)91023-5","article-title":"Scleral buckling surgery for active stage 4A retinopathy of prematurity.","volume":"105","author":"Hinz","year":"1998","journal-title":"Ophthalmology"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.116.11.1446","article-title":"Refractive changes associated with scleral buckling and division in retinopathy of prematurity.","volume":"116","author":"Chow","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archopht.124.1.20","article-title":". Lens clarity after 3-port lens-sparing vitrectomy in stage 4A and 4B retinal detachments secondary to retinopathy of prematurity.","volume":"124","author":"Lakhanpal","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/IAE.0b013e318159ec49","article-title":"25-gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity.","volume":"28","author":"Kychenthal","year":"2008","journal-title":"Retina"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/IAE.0b013e3181610f97","article-title":"Three-year anatomic and visual outcomes after vitrectomy for stage 4B retinopathy of prematurity.","volume":"28","author":"El Rayes","year":"2008","journal-title":"Retina"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1097\/IAE.0b013e3182551c54","article-title":". Intraocular pressure elevation is a delayed-onset complication after successful vitrectomy for stages 4 and 5 retinopathy of prematurity.","volume":"32","author":"Iwahashi-Shima","year":"2012","journal-title":"Retina"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","article-title":"Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity.","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":". Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":". Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":". Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/IAE.0b013e3181ca146b","article-title":"Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.","volume":"30","author":"Kychenthal","year":"2010","journal-title":"Retina"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000338623","article-title":". Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity.","volume":"3","author":"Mota","year":"2012","journal-title":"Case Rep Ophthalmol"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited.","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":". Reactivation of retinopathy of prematurity after bevacizumab injection.","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.earlhumdev.2011.05.009","article-title":"Mediators involved in retinopathy of prematurity and emerging therapeutic targets.","volume":"87","author":"Mataftsi","year":"2011","journal-title":"Early Hum Dev"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/IAE.0b013e31820d4000","article-title":". Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.","volume":"31","author":"Axer-Siegel","year":"2011","journal-title":"Retina"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":". Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye (Lond)"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":". Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/eye.2011.66","article-title":"Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.","volume":"25","author":"Meyer","year":"2011","journal-title":"Eye (Lond)"},{"key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":". Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","author":"Group","year":"2011","journal-title":"N Engl J Med"},{"key":"R34-8-20210130","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","article-title":". Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.","volume":"91","author":"Hoerster","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R35-8-20210130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children.","volume":"16","author":"Blair","year":"2012","journal-title":"J AAPOS"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000000359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:05:54Z","timestamp":1620954354000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201504000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000000359","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}